Louisville, KYNCT05536141Now EnrollingIRB Ready

Clear Cell Renal Cell Carcinoma Clinical Trial in Louisville, KY

Access cutting-edge clear cell renal cell carcinoma treatment through this clinical trial at a research site in Louisville. Study-provided care at no cost to qualified participants.

Sponsored by Arcus Biosciences, Inc.

Quick Self-Assessment

See if you qualify for this Louisville location

Preparing your pre-screening questions…

Expert Care in Louisville

Access clear cell renal cell carcinoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related clear cell renal cell carcinoma treatment provided free

Apply for This Louisville Location

Check if you qualify for this clear cell renal cell carcinoma clinical trial in Louisville, KY

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Louisville

    Convenient for KY residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Louisville site if eligible
  4. 4Begin participation

About This Clear Cell Renal Cell Carcinoma Study in Louisville

The purpose of this study is to evaluate the safety and tolerability of: * casdatifan when taken alone in participants with advanced solid tumor malignancies and clear cell renal cell carcinoma (ccRCC) during the dose escalation stage; and * casdatifan monotherapy and casdatifan in combination with cabozantinib or zimberelimab or zimberelimab and ipilimumab in participants with ccRCC in the dose expansion stage.

Sponsor: Arcus Biosciences, Inc.

Who Can Participate

Inclusion Criteria

Must have at least one measurable lesion per RECIST guidance
Eastern Cooperative Oncology Group (ECOG) performance status score of ≤ 1
Disease-specific criteria for dose escalation:
Participants may have any pathologically confirmed solid tumor type where no other treatment options are available
Creatinine clearance ≥ 40 mL/min Disease-specific criteria for dose-expansion:
Histologically confirmed ccRCC
Creatinine clearance ≥ 40 mL/min Key

Exclusion Criteria

Use of any live vaccines against infectious diseases (eg, influenza, varicella) within 4 weeks (28 days) of initiation of investigational product
Has any other clinically significant cardiac, respiratory, or other medical or psychiatric condition that might interfere with a participant's participation in the clinical study or make the administration of investigational product hazardous
History of trauma or major surgery within 28 days prior to the first dose of investigational product
For all expansion cohorts: prior treatment with an hypoxia inducible factor (HIF)-2α inhibitor. For the casdatifan + cabozantinib combination cohort, any prior treatment with cabozantinib. For casdatifan + zimberelimab and casdatifan + zimberelimab + ipilimumab cohorts, any prior systemic treatment when cancer is present.
Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Louisville?

Yes, this clinical trial (NCT05536141) has an active research site in Louisville, KY that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Clear Cell Renal Cell Carcinoma Treatment Options in Louisville, KY

If you're searching for clear cell renal cell carcinoma treatment options in Louisville, KY, this clinical trial (NCT05536141) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Louisville research site is actively enrolling participants for this clinical trial. You'll receive care from experienced clear cell renal cell carcinoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all clear cell renal cell carcinoma clinical trials near you to find additional studies recruiting in your area.

More Kidney Cancer Trials in Louisville, KY

See all kidney cancer clinical trials recruiting in Louisville — not just this study.

Browse Kidney Cancer Trials in Louisville →

Browse More Trials by Condition

Kidney Cancer TrialsAll Conditions →

Ready to Join in Louisville?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Louisville, KY